Summary
50 / 100 · Bulios Score
What speaks for it
- It has been profitable 6 years in a row.
What to watch
- Revenue grew by only 1.0% a year over the last 3 years.
- Out of every 100 CHF of revenue, only 3.7 CHF is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 25.7 CHF for 1 CHF of yearly profit. Over the last five years it was 20.8 CHF on average.
Valuation in detailIs it growing?
SlowlyRevenue (CHF)
Diluted EPS (CHF)
- Analyst estimate
Revenue grew by 3.5% a year over 5 years. Over the last 3 years it grew by 1.0% a year. For the next fiscal year analysts expect revenue to grow by 2.9%. Earnings per share grew by 3.0% a year over the last 3 years.
Growth in detailDoes it make money?
PoorlyWhere 100 CHF of revenue goes
- Cost of sales 90 CHF
- Sales and administration 5.1 CHF
- Taxes and other 1.1 CHF
- Net profit 3.7 CHF
Net profit, industry median (Medical - Distribution) 1.5 CHF
Out of every 100 CHF of revenue, 3.7 CHF is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 5.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, stretched- Yield
- 1.60%
- Paid out of profit
- 41%
- Raised in a row
- 1 year
You receive $1.59 per share a year. The payout takes a large part of its profit or free cash flow.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.